(Q105171658)

http://api.crossref.org/works/10.1002%2Fhlca.200790143

1 reference

1 reference

(1S,2S,5S,6R,8S,9R,12S,13R,18R,19R)-6-[(2R)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-19-hydroxy-8,18-dimethoxy-6,13-dimethyl-7-oxapentacyclo[10.8.0.02,9.05,9.013,18]icos-15-en-14-one

1 reference

(1R,2S,3S,5S,6R,8S,9R,12S,13R,18R,19R)-6-[(2R)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-3,18,19-trihydroxy-8-methoxy-6,13-dimethyl-7-oxapentacyclo[10.8.0.02,9.05,9.013,18]icos-15-en-14-one

1 reference

(1R,2R,5S,6R,9S,12S,13R,18R,20S)-6-[(2R)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-2-hydroxy-6,13-dimethyl-7,19-dioxahexacyclo[10.9.0.02,9.05,9.013,18.018,20]henicos-15-ene-8,14-dione

1 reference

(1S,2S,5S,6R,8S,9R,12S,13R,16R,18S,20R)-6-[(2R)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-8,16-dimethoxy-6,13-dimethyl-7,19-dioxahexacyclo[10.9.0.02,9.05,9.013,18.018,20]henicosan-14-one

1 reference

(1S,2S,5S,6R,8S,9R,12S,13R,18R,19R)-6-[(2R)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-18,19-dihydroxy-8-methoxy-6,13-dimethyl-7-oxapentacyclo[10.8.0.02,9.05,9.013,18]icos-15-en-14-one

1 reference

Lei Ma

1

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

Xian-Wen Gan

2

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

Qing-Ping He

3

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

Hai-Yun Bai

4

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

Mohammad Arfan

5

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

Feng-Chang Lou

6

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

Li-Hong Hu

7

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

publication date

July 2007

1 reference

16 September 2022

Helvetica Chimica Acta

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

volume

90

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

issue

7

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

page(s)

1406-1419

1 reference

http://api.crossref.org/works/10.1002%2Fhlca.200790143

cites work

Withanolides and related ergostane-type steroids

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Actin microfilament aggregation induced by withaferin A is mediated by annexin II.

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Trypanocidal withanolides and withanolide glycosides from Dunalia brachyacantha

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Induction of quinone reductase by withanolides.

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Steroidal constituents of Physalis minima(Solanaceae)

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Withaphysalin D, a new withaphysalin from Physalis minima Linn. var. indica.

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Withaphysalin E, a withanolide of Physalis minima var. indica☆

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

18,20-Hemiacetal-type and Other Withanolides fromDunaliabrachyacantha

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Withanolides from Vassobia lorentzii.

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Cytotoxic withaphysalins from the leaves of Acnistus arborescens

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Cytotoxic withanolides from Physalis angulata L.

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Withajardins, withanolides with a new type of skeleton structure of withajardins A, B, C and D absolute configuration of withajardin C

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Spiranoid withanolides from Jaborosa odonelliana

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FHLCA.200790143

7 January 2021